# Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

> **NCT03359590** · PHASE2 · COMPLETED · sponsor: **Profil Institut für Stoffwechselforschung GmbH** · enrollment: 20 (actual)

## Conditions studied

- Pharmacological Action

## Interventions

- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03359590
- **Lead sponsor:** Profil Institut für Stoffwechselforschung GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359590, "Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03359590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*